Infinity Pharmaceuticals Inc and AbbVie to Discuss Strategic Collaboration In Oncology Conference Call Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Sep 3 Calls
Today's Calls
Call Details
Infinity Pharmaceuticals Inc and AbbVie to Discuss Strategic Collaboration In Oncology Conference Call
Wed, Sep 3, 2014, 8:30 am Eastern

Listen to the archived event audio


About Infinity Pharmaceuticals Inc (NasdaqGS:INFI)
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.


More Info: Quote | Profile | Research | Insider | Financials | Analyst Ratings
About AbbVie Inc (NYSE:ABBV)
AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.


More Info: Quote | Profile | Research | Insider | Financials


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.